AbbVie announced a $380 million investment to expand its manufacturing operations in North Chicago, Illinois. The pharmaceutical company is expanding U.S. production capacity at a moment when supply chain disruptions and tariff uncertainty are reshaping corporate decisions about where to manufacture.
For North Chicago residents and Illinois workers, the expansion means job creation. AbbVie has not said how many positions will be added. The company manufactures treatments for immunology, oncology, and other therapeutic areas at the North Chicago site.
The expansion will upgrade and modernize AbbVie's existing North Chicago facility, one of the company's largest manufacturing hubs. The investment covers equipment, infrastructure, and technology upgrades designed to increase production capacity and improve efficiency.
Industry analysts estimate that manufacturing expansions of this scale create between 100 and 300 positions across direct employment, construction, and supply chain roles. AbbVie has not provided a construction schedule or hiring timeline. The company declined to say when work will begin or finish.
AbbVie says its investment reflects a growing corporate trend toward U.S. expansion. Pharmaceutical companies face pressure to reduce dependence on overseas suppliers, particularly for critical medicines.
Since January 2025, only the $420 million Ford battery project in Joliet exceeds AbbVie's announced spend in Illinois, according to the Illinois Department of Commerce. The investment supports North Chicago's economy at a time when the region faces industrial challenges.
The company stated that the investment reflects its commitment to U.S. manufacturing and its confidence in the North Chicago location as a strategic production center.
AbbVie announced a $380 million investment to expand its manufacturing operations in North Chicago, Illinois. The pharmaceutical company is doubling down on U.S. production capacity at a moment when many manufacturers are still deciding whether to bring operations home or keep them overseas.
For North Chicago residents and Illinois workers, this means real jobs. The investment signals that at least one major employer sees the region as worth betting on for the next decade. Manufacturing jobs in the pharmaceutical sector typically pay $50,000 to $80,000 annually, well above the median wage in the region.
The expansion will upgrade and modernize AbbVie's existing North Chicago facility, one of the company's largest manufacturing hubs. The investment covers equipment, infrastructure, and technology upgrades designed to increase production capacity and improve efficiency. AbbVie did not announce a specific number of new jobs, but manufacturing expansions of this scale typically create between 100 and 300 positions across direct employment, construction, and supply chain roles.
The timing matters. AbbVie's decision comes as pharmaceutical companies face pressure to reduce their dependence on overseas suppliers, particularly for critical medicines. The company manufactures treatments for immunology, oncology, and other therapeutic areas at the North Chicago site.
The investment reflects a broader shift in how major corporations view U.S. manufacturing. For years, companies moved production to countries with lower labor costs. Now, supply chain disruptions, tariff uncertainty, and government incentives are making domestic production more attractive again.
For Illinois specifically, this is one of the largest private manufacturing commitments announced in the state recently. It anchors North Chicago's economy and provides a counterweight to decades of industrial decline in the region. The facility will remain a major employer in Lake County for years to come.
AbbVie did not announce a timeline for when the expansion would be complete or when new positions would be filled. The company said the investment reflects its commitment to U.S. manufacturing and its confidence in the North Chicago location as a strategic production center.
Highlighted text was flagged by the council. Tap to see feedback.
